A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
نویسندگان
چکیده
منابع مشابه
Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan.
UNLABELLED Abstract Objective: To assess the impact of nonuniform dose distribution within lesions and tumor-involved organs of patients receiving Zevalin(®), and to discuss possible implications of equivalent uniform biological effective doses (EU-BED) on treatment efficacy and toxicity. MATLAB™ -based software for voxel-based dosimetry was adopted for this purpose. METHODS Eleven lesions fr...
متن کاملAccurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
UNLABELLED This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting radiopharmaceutical (90)Y-ibritumomab tiuxetan. METHODS Five different facilities independently measured (90)Y in a 10-mL syringe geometry with 30 dose calibrator models from 3 different manufacturers. The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the vol...
متن کاملDetection of 90Y extravasation by bremsstrahlung imaging for patients undergoing 90Y-ibritumomab tiuxetan therapy.
UNLABELLED Extravasation of therapeutic (90)Y-ibritumomab tiuxetan can cause significant injury. Detection of extravasated (90)Y using a γ-camera for patients undergoing (90)Y-ibritumomab tiuxetan therapy is a challenge because of the inherently low efficiency of bremsstrahlung imaging and the interference of prompt and scattered photons from (111)In that are still present in the body at the ti...
متن کاملDynamic Metabolic Changes during the First 3 Months after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy
OBJECTIVE To elucidate the time course of tumor metabolism during the first 3 months after (90)Y-ibritumomab tiuxetan radioimmunotherapy (RIT) in patients with refractory malignant lymphoma. MATERIALS AND METHODS Seven patients with recurrent follicular lymphoma underwent FDG-PET imaging before and after 1-, 4-, and 12-week RIT with (90)Y-ibritumomab tiuxetan. Tumor metabolic activity on FDG-...
متن کاملUpdate on the rational use of 90Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
The development of radiolabeled antibodies against CD20 has facilitated targeted treatment of follicular lymphoma (FL). By using (90)Y-ibritumomab tiuxetan (Zevalin((R))), a radionuclide (yttrium-90, linked by the chelator tiuxetan to the antibody ibritumomab) is brought into the vicinity of lymphoma cells. By the so-called cross-fire effect, this beta emitter has the capacity to destroy not on...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2018
ISSN: 2045-2322
DOI: 10.1038/s41598-018-33160-0